Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Shares Shorted: Short Interest Down 64.6% in October

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 34 shares, a decrease of 64.6% from the October 15th total of 96 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Basilea Pharmaceutica Price Performance

BPMUF remained flat at $84.00 during midday trading on Monday. The company has a current ratio of 6.60, a quick ratio of 5.97 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $77.15 and its two-hundred day simple moving average is $70.00. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $84.00.

Basilea Pharmaceutica Company Profile

(Get Free Report)

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.

Featured Stories

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.